AxoGen, Inc. (AXGN) Stock Price & How to Invest
Last updated July 2026
Short answer
AXGN is Axogen, a commercial-stage medtech company that makes surgical products for repairing peripheral nerves, with real and growing product revenue (~$225M in 2025) rather than a pre-revenue story. Investing in it is a bet on continued adoption of nerve-repair procedures plus the newly FDA-approved Avance biologic, balanced against a small-cap profile and a company still working toward consistent profitability.
AXGN stock price
As of 2026-07-10, AxoGen, Inc. (AXGN) last closed at $40.58, up 241.3% over the past year. Over the past 52 weeks it has traded between $11.28 and $46.19.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or AxoGen, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does AxoGen, Inc. (AXGN) do?
Axogen (AXGN) develops and sells products used by surgeons to repair and reconstruct peripheral nerves, the nerves outside the brain and spinal cord that carry signals to muscles and skin. Its portfolio centers on Avance, an acellular (processed human donor) nerve graft used to bridge gaps where a nerve has been cut, along with the Axoguard family of nerve connectors and protective wraps. These products are used in hand and upper-extremity trauma, breast reconstruction (restoring sensation), oral and facial surgery, and other reconstructive settings. Axogen sells through a specialized US sales force and reported full-year 2025 revenue of ~$225M, up ~20% year over year, with gross margins in the mid-70s percent range.
The investment picture is that of a focused, still-scaling medtech leader in a narrow but expanding niche. A major milestone came in December 2025 when the FDA approved the Biologics License Application (BLA) for Avance, making it the first approved biologic for peripheral nerve discontinuities and granting 12 years of market exclusivity. Alongside that, a new 2026 CMS reimbursement code raised facility payment for Avance procedures meaningfully, which supports adoption. Axogen has guided to at least ~20% revenue growth in 2026 (roughly $270M) and expects to move toward free-cash-flow-positive operations, though it has historically run near or below breakeven on a net-income basis, so profitability consistency is a key thing to watch.
What's driving AxoGen, Inc. (AXGN)?
1. Avance FDA approval and exclusivity
The December 2025 BLA approval made Avance the first FDA-approved biologic for peripheral nerve discontinuities, with 12 years of market exclusivity. This can strengthen surgeon confidence, support pricing, and create a regulatory moat around the core product that competing off-the-shelf conduits and wraps do not carry.
2. Reimbursement tailwind
Effective January 2026, CMS created a new Level 3 Nerve Procedure Code that raised Avance facility reimbursement roughly 40% year over year for hospital outpatient settings and about 35% for ambulatory surgery centers. Better economics for hospitals and surgeons can lower a practical barrier to using Avance over alternatives.
3. Procedure and indication expansion
Growth is tied to expanding use across trauma, breast reconstruction sensory restoration, oral and facial surgery, and other reconstructive areas. Deeper penetration of existing accounts plus new surgeon adoption and clinical evidence are the main levers behind the guided ~20% revenue growth.
4. Path toward cash-flow-positive operations
Axogen has scaled revenue past $225M with mid-70s gross margins and reported positive adjusted EBITDA for 2025. Management has pointed toward free cash flow positive operations in 2026, so operating leverage as revenue grows is a central part of the longer-term thesis.
What are the risks to AxoGen, Inc. (AXGN)?
Axogen is a small-cap medical device and biologics company, so the shares can be volatile and sensitive to quarterly results and guidance changes. The business depends heavily on one core product franchise (Avance and Axoguard) and on a supply of processed human donor nerve tissue, which introduces concentration and supply risk. Reimbursement policy can move in either direction, and larger, better-capitalized competitors such as Integra LifeSciences, Stryker, and Baxter sell alternative conduits and wraps. The company has operated near breakeven on net income historically and has used equity offerings to fund the business, which can dilute shareholders. Adoption of nerve-repair procedures, clinical evidence, and consistent margin execution all remain uncertain.
How is AxoGen, Inc. (AXGN) valued? (approximate, JULY 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see AxoGen, Inc.'s investor relations page or your broker.
- Revenue (FY2025): ~$225M
- Revenue growth (2025): ~20% YoY
- Gross margin: ~74-76%
- Q1 2026 revenue: ~$61.5M (up ~27% YoY)
- 2026 revenue guidance: ~$270M (>=20% growth)
- Market cap: ~$1.7-1.8B
Axogen trades as a growth-oriented small-cap medtech, so its valuation reflects expected revenue expansion rather than current earnings, which have historically hovered near breakeven. The 2025 Avance approval and 2026 reimbursement increase reshaped the story, and the stock has been reactive to guidance updates. Figures are approximate and as of JULY 2026.
Who competes with AxoGen, Inc. (AXGN)?
Nerve-repair and biomaterials medtech
Integra LifeSciences, Stryker, and Baxter International sell off-the-shelf nerve conduits, connectors, and bio-absorbable wraps that compete with parts of Axogen's portfolio. These are larger, diversified companies with broader surgical footprints and deeper resources.
Large diversified device makers
Medtronic and other large device companies operate in adjacent neuro and surgical categories and could expand into nerve repair or apply competitive pressure through bundled surgical relationships, even where they do not directly match Avance today.
Autograft and surgical alternatives
The traditional standard of care, taking a nerve graft from elsewhere in the patient's own body (autograft), and direct suture repair remain the main clinical alternatives Axogen's processed allograft and connectors compete against, so surgeon preference and evidence matter as much as rival products.
How to invest in AxoGen, Inc. (AXGN)
There are three common ways to get AXGN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so AXGN sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where AXGN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on AxoGen, Inc. (AXGN)
AXGN is a growing, niche nerve-repair medtech with a landmark 2025 FDA approval driving the story, but it stays a small-cap where execution and margins matter more than the narrative.
More on AxoGen, Inc. (AXGN)
Whether AXGN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AXGN a buy?, and where the stock could go from here in the AXGN stock forecast.
For income investors, whether AXGN pays a dividend and how the payout looks is covered in does AXGN pay a dividend?
Build a basket around AXGN with Walnut
Use AxoGen, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Axogen do?
+
Axogen develops and sells surgical products that repair and reconstruct peripheral nerves, the nerves outside the brain and spinal cord. Its main products are the Avance nerve graft and the Axoguard family of nerve connectors and protective wraps, used in trauma, breast reconstruction, and facial surgery.
Is AXGN a profitable company?
+
Axogen generates substantial product revenue (~$225M in 2025) with mid-70s percent gross margins and reported positive adjusted EBITDA for 2025, but it has historically operated near breakeven on net income. Management has pointed toward free-cash-flow-positive operations in 2026, so profitability consistency is still being established.
What was the FDA approval about?
+
In December 2025 the FDA approved the Biologics License Application for Avance, making it the first approved biologic for peripheral nerve discontinuities. The approval came with 12 years of market exclusivity, which can support surgeon confidence and pricing for the core product.
How fast is AXGN growing?
+
Full-year 2025 revenue rose about 20% to roughly $225M, and first-quarter 2026 revenue was about $61.5M, up roughly 27% year over year. The company has guided to at least ~20% revenue growth for 2026, to roughly $270M.
Who are Axogen's main competitors?
+
Integra LifeSciences, Stryker, and Baxter International sell competing nerve conduits and wraps, and larger device makers such as Medtronic operate in adjacent categories. The traditional clinical alternatives are the patient's own nerve graft (autograft) and direct suture repair.
What are the main risks with AXGN?
+
Key risks include its small-cap volatility, heavy reliance on one product franchise, dependence on a supply of processed donor nerve tissue, reimbursement policy shifts, competition from larger firms, a history of operating near breakeven, and past use of equity offerings that can dilute shareholders.
How does the 2026 reimbursement change affect Axogen?
+
Starting January 2026, CMS created a new Level 3 Nerve Procedure Code that raised Avance facility reimbursement roughly 40% for hospital outpatient settings and about 35% for ambulatory surgery centers. Higher reimbursement can make it easier for hospitals and surgeons to choose Avance.
How can someone invest in AXGN?
+
AXGN trades on the Nasdaq, so it can be bought through a brokerage account like any US-listed stock. Walnut is not an investment adviser and does not tell you whether to buy it; anyone considering it should weigh its growth, its small-cap risk profile, and their own goals and risk tolerance, ideally with a licensed professional.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with AxoGen, Inc.'s investor relations page or your broker before making investment decisions.